AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00122304
Drug: eculizumab
RxNorm normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03131843
Drug: No alcohol
RxNorm normalized name: BENZALKONIUM CHLORIDE 0.13 g in 100 mL TOPICAL SOLUTION [Zoono Alcohol Free Hand Sanitizer]
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No alcohol will be used; alcohol cleansing swab/wipe will be used at a different injection site
Trial: NCT02435537
Drug: Dexmedetomidine (Precedex)
RxNorm normalized name: dexmedetomidine Injection [Precedex]
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intrathecal administration
Trial: NCT02435537
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intrathecal 10 mg bupivacaine
Trial: NCT02435537
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intrathecal 0.5mg morphine
Trial: NCT00128232
Drug: Octreotide LAR
RxNorm normalized name: octreotide LAR 20 MG Injection
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04430556
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline will be started in all patients, unless it is contraindicated, in this case, Escitalopram will be indicated.
Trial: NCT02744833
Drug: GMI-1271
RxNorm normalized name: GMI-1070
DrugBank: Rivipansel (DB12778)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01580670
Drug: TA-650
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TA-650 will be intravenously infused at 5 mg/kg as an induction regimen at Week 0, 2, 6. For subjects who meet the responder criteria, TA-650 will be administered at 8-week intervals thereafter until week 46. If the criteria for a dosage escalation are met, TA-650 will be administered at a dosage of 10 mg/kg.
Trial: NCT00175149
Drug: Alfacalcidiol
RxNorm normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidiol are given to patientwith CKD 3-4 and secondary hyperparathyrodism. The PTH level is lowered to normal range. with increasing dose of alfacalcidiol and are followed for 6 month.
Trial: NCT00460811
Drug: Linaclotide Acetate
RxNorm normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral, once daily
Trial: NCT02744833
Drug: Enoxaparin Sodium (Lovenox®)
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02097745
Drug: rituximab [MabThera/Rituxan]
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1 g given by intravenous infusion on Days 1 and 15 of each treatment course
Trial: NCT02748356
Drug: Lactobacillus
RxNorm normalized name: lactobacillus
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients will undergo 1 Lactobacillus pediatric dose (Culturelle GG 10 Billion live organisms) instillation by study personnel at the study site. For the intravesicular Lactobacillus instillation, the contents of 1 Lactobacillus capsule will be mixed into sterile 0.9% saline using an age-based estimate of bladder capacity. Similar to adults, this bladder instillation will represent 10% of the estimated maximum bladder volume based on age.
Trial: NCT01071564
Drug: Vismodegib
RxNorm normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT01359852
Drug: [11C] JNJ-42491293 + JNJ-40411813
DrugBank: JNJ-40411813 (DB12059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part C:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v.bolus injection. Volunteers will be pre-treated with JNJ-40411813 between 1.5 to 3 hours prior to the second and prior to the third PET scan
Trial: NCT01359852
Drug: [11C] JNJ-42491293 + JNJ-40411813
DrugBank: JNJ-40411813 (DB12059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part D:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection.~Volunteers will be treated with a single dose of up to 500 mg JNJ-40411813 prior to the second scan and will have a third scan at least 2 hours later to evaluate the rate of clearance of JNJ-40411813 from the brain
Trial: NCT00525785
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2.2 Gm/m\^2 By Vein Over 48 Hours On Days 1, 15, 29, and 43.~Chemoradiotherapy: 300 mg/m2 a day Monday through Friday, by continuous infusion during radiation through an outpatient portable pump.
Trial: NCT00525785
Drug: Folinic Acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m\^2 by vein Over 30 Minutes On Days 1, 15, 29, and 43.
Trial: NCT00525785
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg/m\^2 By Vein Over 2 Hours On Days 1, 15, 29, and 43.~Chemoradiotherapy: 45 mg/m\^2 over 2 hours weekly for 5 weeks during radiation. (oxaliplatin should be administered on the first day of the radiation week).
Trial: NCT00364923
Drug: Pralatrexate Injection
RxNorm normalized name: pralatrexate Injection
DrugBank: Pralatrexate (DB06813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pralatrexate 30 mg/m2 via IV push over 3-5 minutes for 6 weeks in a 7 week cycle.
Trial: NCT00425750
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.6 mg/m2 through a vein on days 1 and 8 of a 21-day cycle. The first dose is given as a single agent only on Day 1 of Cycle 1.
Trial: NCT00425750
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg/m2 through a vein on days 1 and 8 of a 21-day cycle except the first dose is held only on Day 1 of Cycle 1.
Trial: NCT05333302
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Before 1h of CAR-T cells infusion a patient receive tocilizumab (8 mg/kg).
Trial: NCT02589639
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00813384
Drug: AMG 208
RxNorm normalized name: AMG-208
DrugBank: AMG-208 (DB08079)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 208 is a small molecule inhibitor of c-Met which is a well-characterized receptor tyrosine kinase expressed on the surface of epithelial cells. C-Met receptor signaling has been shown to play a key role in the survival of cancer cells. AMG 208 inhibits both ligand-dependent and ligand-independent c-Met cellular growth regulation. Inhibition of c-Met signaling with AMG 208 provides a potential mechanism for blocking tumor growth and survival.
Trial: NCT01276756
Drug: Pegylated interferon alfa-2a
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon 160ug once weekly 48 weeks
Trial: NCT01276756
Drug: Nitazoxanide
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitazoxanide 500mg twice daily 4 weeks lead-in followed by triple therapy 48 weeks
Trial: NCT01276756
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin (\> 75kg:1200 mg, \<75kg:1000mg daily)48 weeks
Trial: NCT02596555
Drug: Dabigatran
RxNorm normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin for 72 hours followed by 6 months of dabigatran
Trial: NCT01877642
Drug: Lorazepam 1 mg IM
RxNorm normalized name: lorazepam 1 MG
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lorazepam 1 mg intramuscular
Trial: NCT01877642
Drug: Inhaled loxapine 10 mg
RxNorm normalized name: loxapine Inhalant Product
DrugBank: Loxapine (DB00408)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled Staccato loxapine 10 mg
Trial: NCT01082705
Drug: Dihydroartemisinin-piperaquine
RxNorm normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily for 3 days as tablets containing 40 mg of dihydroartemisinin and 320 mg of piperaquine at a total dosage of 6.4 mg/kg of dihydroartemisinin and 51.2 mg/kg of piperaquine divided equally between the three days
Trial: NCT04615403
Drug: Travoprost
RxNorm normalized name: Travoprost
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Implantation and exchange of a Travoprost Intraocular Implant through a clear corneal incision
Trial: NCT02980068
Drug: 15N Nitrate
RxNorm normalized name: sodium nitrate 15N
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1,000 mg/11.8 mmol, oral, on day one, hour zero
Trial: NCT02980068
Drug: 14N Nitrate
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg/11.18 mmol, oral, on day hour, hour zero
Trial: NCT00274274
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00274274
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03771560
Drug: folinic acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: subject will take folinic acid daily for 12 weeks
Trial: NCT00330993
Drug: mifepristone, misoprostol
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01812954
Drug: Cyclosporins
RxNorm normalized name: Cyclosporine
DrugBank: Cyclo(his-pro) (DB02414)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01812954
Drug: fumaric acid
RxNorm normalized name: Fumaric Acid
DrugBank: Fumaric acid (DB01677)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01812954
Drug: Acitretin
RxNorm normalized name: Acitretin
DrugBank: Acitretin (DB00459)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01812954
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01812954
Drug: etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02205164
Drug: Palonosetron + Aprepitant
RxNorm normalized name: Aprepitant
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aloxi 0.25mg Emend 125/80/80 mg
Trial: NCT02205164
Drug: Palonosetron
RxNorm normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aloxi 0.25mg
Trial: NCT01812954
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01812954
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02768727
Drug: Xenon
RxNorm normalized name: xenon
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drug given in concentrations of 0% to 60% over period of 2 hours
Trial: NCT03894189
Drug: Doxapram Hydrochloride
RxNorm normalized name: Doxapram Hydrochloride
DrugBank: Doxapram (DB00561)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the diaphragmatic function will be assessed measuring right and left diaphragmatic thickening fraction in the two groups to be compared as a primary outcome using ultrasound. following the administration of the selected drug
Trial: NCT00604591
Drug: Tolcapone
RxNorm normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg by mouth three times a day
Trial: NCT02318446
Drug: Saccharine
RxNorm normalized name: Saccharin
DrugBank: Saccharin (DB12418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group(n=12) Existing Anti-epileptic Drugs + Oral saccharine 10 mg tablet daily for 1month
Trial: NCT00713947
Drug: Pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 months at 20 mg
Trial: NCT03039049
Drug: Triptorelin 0.1 mg
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a single dose of Triptorelin 0.1 mg subcutaneously administered 6 days after oocyte retrieval.
Trial: NCT01894334
Drug: Ulinastatin
RxNorm normalized name: ulinastatin
DrugBank: Ulinastatin (DB12038)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01894334
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01894334
Drug: Edaravone
RxNorm normalized name: Edaravone
DrugBank: Edaravone (DB12243)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02502682
Drug: Sage 2% Chlorhexidine Gluconate Cloth Patient Preoperative Skin Preparation
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily bathing.
Trial: NCT02195869
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02073929
Drug: Liraglutide for 26 weeks
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: GLP-1-analogue Liraglutide s.c. 1,8mg daily for 26 weeks
Trial: NCT02934698
Drug: Ivacaftor
RxNorm normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will be treated with ivacaftor for 6 months and followed for 7 months and will undergo assessments along the way to measure sweat chloride and sputum amounts.
Trial: NCT00433589
Drug: tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00433589
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04423744
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT03972189
Drug: TQ-B3101
RxNorm normalized name: TQS-168
DrugBank: TQS-168 (DB18108)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQ-B3101 300 mg given orally in fasting conditions, twice daily in 28-day cycle.
Trial: NCT01124760
Drug: Diltiazem
RxNorm normalized name: Diltiazem
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally, daily beginning on Day 4 for 14 consecutive days
Trial: NCT01124760
Drug: ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg, orally, every 12 hours starting on Day 4 for 10 consecutive days in which on Day 13 only the morning dose will be administered
Trial: NCT03177460
Drug: FMS Inhibitor JNJ-40346527
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: JNJ-40346527 (DB12504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00072280
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV over 1 hour, dose 3.3 mg/kg in normal saline (NS) 10 cc/kg (or to equal 0.4 mg/mL concentration) on days 1-5 of IE cycle.
Trial: NCT00072280
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV over 1 hour, dose 60mg/kg in D5 1/4 NS 10 cc/kg IV on days 1-5 of IE Cycle
Trial: NCT00072280
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV Push over 1 minute, dose 0.05 mg/kg (max dose 2 mg) on days 1,8,15,22,29,36,43,50,57 and 64
Trial: NCT01743560
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer were to be treated with oral tablet RAD001 at a dose of 10mg daily and oral tablet exemestane 25mg daily. The study treatment for an individual patient was to begin on Study Day 1 and continue until the last patient enrolled completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
Trial: NCT00481351
Drug: ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ezetimiba 10mg once a day
Trial: NCT01441765
Drug: CT-011
RxNorm normalized name: CT-011
DrugBank: CT-011 (DB05916)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-011 at 3 mg/kg IV for 4 cycles of 6 weeks
Trial: NCT01924832
Drug: dimethyl fumarate
RxNorm normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT02693470
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 50 patients with severe psoriasis received ustekinumab 45mg at 0 and 1 month. There were 50 healthy controls. The levels of circulating CD31 and CD41a positive microparticles are measured. In patients with psoriasis, the investigators measure microparticles in the baseline and 4 months after ustekinumab. For control group, the investigators measure microparticles in the baseline.
Trial: NCT01259622
Drug: saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT01259622
Drug: K201
RxNorm normalized name: K201 free base
DrugBank: K201 free base (DB02929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT03821168
Drug: injection of bevacizumab and erythropoietin
RxNorm normalized name: bevacizumab Injection
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection of bevacizumab and erythropoietin
Trial: NCT03821168
Drug: injection of bevacizumab
RxNorm normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: under gone 3 intravitreal injection of bevacizumab monthly and examine monthly for Visual acuity and central macular thickness
Trial: NCT02328885
Drug: DLI of the 20 fraction of the UCBT
RxNorm normalized name: Extract of the Sterile Caules of Equisetum Arvense
DrugBank: Equisetum arvense top (DB14349)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 20 fraction of the UCBT
Trial: NCT03399032
Drug: Caspofungin
RxNorm normalized name: Caspofungin
DrugBank: Caspofungin (DB00520)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each patient will receive: caspofungin i.v. once daily ( 70 mg on the first day, 50 mg on the 2 and 3 day~Blood samples (3 mL) will be collected 2, 4, 8, 12 and 24 hours after each dose of caspofungin for 3 consecutive days.
Trial: NCT04170738
Drug: Adderall
RxNorm normalized name: Adderall
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 weeks of Adderall
Trial: NCT03341845
Drug: Axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: axitinib in combination with avelumab
Trial: NCT03341845
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: axitinib in combination with avelumab
Trial: NCT00570687
Drug: Technosphere Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhalation 15U/30U
Trial: NCT03055338
Drug: MK-8189
RxNorm normalized name: MK-8189
DrugBank: MK-8189 (DB19153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral CR tablets (4 mg) administered QD at the following dose strengths: 4 mg (1 tablet); 8 mg (2 tablets); 12 mg (3 tablets)
Trial: NCT03055338
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral capsules (2 mg) administered QD at the following dose strengths: 2 mg (1 capsule); 4 mg (2 capsules); 6 mg (3 capsules)
Trial: NCT03055338
Drug: Placebo matching MK-8189
RxNorm normalized name: MK-8189
DrugBank: MK-8189 (DB19153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo tablet(s) matching the MK-8189 tablet, administered QD.
Trial: NCT03055338
Drug: Placebo matching risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral placebo capsule(s) matching the risperidone capsule, administered QD.
Trial: NCT00803790
Drug: alendronate sodium+vitamin D combination
RxNorm normalized name: Alendronate Sodium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose tablet of 70mg alendronate sodium+5600 IU vitamin D combination tablet in one treatment period of each sequence.
Trial: NCT03236961
Drug: Ertapenem
RxNorm normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: I.v. ertapenem 1 g for 2 days followed by p.o. levofloxacin 500 mg x1 and metronidazole 500 mg x 3 for 5 days
Trial: NCT03236961
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: P.o. moxifloxacin 400 mg x1 for 7 days
Trial: NCT01028547
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: single Bolus dose of dexamethasone 8mg
Trial: NCT04173780
Drug: Atropine 0.01%
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 drop per day in both eyes for 1 year
Trial: NCT00975611
Drug: Amantadine Hydrochloride, USP
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amantadine tablets 100 mg. BID for 4 weeks